MYC and glioblastoma: In glioblastoma, PRMT5 activity conferred therapeutic resistance to mammalian target of rapamycin (mTOR) inhibitors by mediating the methylation of heterogeneous nuclear ribonucleoprotein 1 (hnRNP A1) to promote the translation of cyclin D1 and c-MYC, leading to drug resistance (Table 2) (Holmes et al., 2019).